In recent years, targeted therapies have raised increasing interest as effective strategies to
improve therapeutic efficiency, reduce the impact of adverse side effects, and overcome …

Conjugates of cytotoxic agents with RGD peptides (Arg-Gly-Asp) addressed to ανβ3, α5β1
and ανβ6 integrin receptors overexpressed by cancer cells, have recently gained attention …

Angiogenesis, formation of new blood vessels from the existing vascular network, is a
hallmark of cancer cells that leads to tumor vascular proliferation and metastasis. This …

Interfering with interactions of vascular endothelial growth factors (VEGFs) with their
receptors (VEGFRs) effectively inhibits angiogenesis and tumor growth. We designed an …

Existing long α-helix mimicking necessitates the retention of most natural amino acid
residues to maintain their biological activity. Here, we report the exploration of helical …

Pro-angiogenic therapy provides a promising new perspective in tackling of many common
and severe pathological conditions, such as central and peripheral vascular diseases. Pro …

Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are pivotal
regulators of angiogenesis. The VEGF–VEGFR system is therefore an important target of …

Peptide drugs have the advantages of target specificity and good drugability and have
become one of the most increasingly important hotspots in new drug research in biomedical …

QK peptide is a vascular endothelial growth factor (VEGF)‐mimetic molecule with significant
proangiogenic activity. In particular, QK is able to bind and activate VEGF receptors …

BAG3, member the HSP70 co-chaperones family, has been shown to play a relevant role in
the survival, growth and invasiveness of different tumor types. In this study, we investigate …